StemCell Therapy

Northern Ireland mum fighting MS: Russian medics are now my last hope

BelfastTelegraph.co.uk

A young Co Down mum is bravely undergoing a gruelling stem cell transplant in Russia in what she believes is her last hope of enjoying some quality of life.

http://www.belfasttelegraph.co.uk/news/northern-ireland/northern-ireland-mum-fighting-ms-russian-medics-are-now-my-last-hope-36023340.html

http://www.belfasttelegraph.co.uk/life/features/article36023337.ece/4289a/AUTOCROP/h342/2017-08-12_lif_33652492_I8.JPG

A young Co Down mum is bravely undergoing a gruelling stem cell transplant in Russia in what she believes is her last hope of enjoying some quality of life.

Lindsay Rice (35) from Warrenpoint has exhausted every treatment on the health service - including chemotherapy normally given to cancer patients - in the hope of treating the chronic condition Rapidly Evolving Severe Relapsing Remitting Multiple Sclerosis.

Paralysis and temporary sight loss are just a few of the many debilitating symptoms which have left the mum-of-two unable to enjoy normal family life.

Desperate to get her help, her family launched an appeal on Facebook and Go Fund Me to raise 50,000 to send her to the National Pirogov Medical Surgical Centre in Moscow where she arrived two weeks ago to start her stem cell transplant.

The treatment alone is expected to cost up to 45,000 and, incredibly, in just 12 weeks the family has raised 32,000 towards a 50,000 target thanks to generous support from friends and the public.

Lindsay, who is married to Liam (36), a financial advisor, has two children, Jamie (17) and Olivia (8).

Liam says: "This is her last hope and she is doing it for her family and her kids and that's what she is focusing on. She just wants to be able to live a normal life and do normal things with the family."

Since starting her treatment on August 1 she has been keeping a daily dairy of her progress through a Facebook page - Lindsay's Last Hope.

While the groundbreaking treatment known as HSCT (Haematopoietic Stem Cell Transplant) is not a cure for MS, Lindsay's hope is that it will halt the progression of the disease and stop the frequent and severe relapses which are destroying her health.

Lindsay will spend a month in the clinic, most of it in isolation, and when she comes home she faces a long recovery period when she will have to remain isolated for up to a year due to the risk of infection.

HSCT aims to 'reset' the immune system to stop it attacking the central nervous system. It uses chemotherapy to remove the harmful immune cells and then rebuild the immune system using a type of stem cell found in the patient's bone marrow.

The haematopoietic stem cells used in the treatment can produce all the different cells in the blood, including immune cells. However, they can't regenerate permanently damaged nerves or other parts of the brain and spinal cord.

Lindsay has successfully had over two million stem cells extracted in a tough procedure which involved having a catheter inserted into her jugular vein. She has also had her head shaved this week in preparation for starting chemotherapy today.

The chemotherapy will wipe out her immune system and she will then have her stem cells transplanted back into her blood by a drip to help regrow a new, stronger immune system.

She will then have to spend 10 days in complete isolation while her new immune system builds.

Also, since arriving in Russia she has been told that her MS is now much worse than she realised and is now at the Secondary Progressive stage.

People with Secondary Progressive MS don't tend to recover completely from a relapse and can expect a general worsening of symptoms, making the treatment even more time-critical.

In a further blow, tests have picked up a potentially dangerous three-centimetre active lesion on her spine which wasn't spotted during MRI's here.

Lindsay faces a tough few weeks in her bid to halt the progression of the disease but as her husband Liam explains, the alternative is the prospect of life in a wheelchair: "Lindsay has come through a lot since her teens.

"She had Jamie quite young at 18 and her condition seemed to really deteriorate after that. She went to a lot of consultants and had many tests but it wasn't until after she had Olivia that she was finally diagnosed in 2011.

"She never knows from day to day how it will affect her. Fatigue is the number one problem and that is crippling. I would come home from work and after dinner she has to go to bed, and even sleep doesn't help it.

"It stops her from doing simple things like taking our daughter to the park or taking the dog for a walk.

"Her motability is not as good as an average person and the other big issue is the relapses.

"They have become very frequent and each relapse is worse in terms of how severe it is. During her last one in February she had to go into hospital and also had to use a walking frame.

"A common misconception is that after each relapse you go back to normal but that's not the case. It leaves its mark and any damage done is permanent. The nature of the relapses could leave her in a wheelchair."

It was after her last relapse and having exhausted all options for treatment on the Health Service that Lindsay decided she wanted to try HSCT.

Her neurologist in Belfast supported her decision and the family applied to the Russian clinic just 12 weeks ago expecting to wait up to two years before admission.

They were surprised to be offered a cancellation on August 1 leaving them facing a race against time to raise 50,000 to cover the cost of treatment and expenses.

Liam says: "We thought we would have at least 12 months and up to two years to get the money together and it has been amazing to see how people have rallied round and what they have done just from the kindness of their hearts, especially strangers.

"We've had quizzes and coffee mornings and online auctions and I recently did the Four Peaks challenge with a group of friends. Lindsay's mum and her best friend are organising a lot of events and we still have some way to go but we are amazed at how much has been raised and donated in such a short time."

Liam flew to Russia with Lindsay on July 31 and stayed with her for five days while she underwent tests to determine that she was suitable for the treatment.

It has already been a punishing two weeks for Lindsay who has come through a batch of invasive procedures including having a catheter inserted in her jugular to extract the stem cells.

Liam says: "It is an intense treatment and Lindsay is so positive and coping brilliantly. She got her hair cut short before she went and decided to have it shaved this week before the chemo starts and it falls out.

"She will have to spend 10 days in complete isolation to allow her immune system to build again and that will be tough.

"She will hopefully be home after 30 days and then when she comes home she will have a long recovery and will have to isolate herself from society for up to a year to keep her safe from infection.

"We will have to deep clean the house and we will all have to wear face masks as she can't risk even getting a cold."

Liam is back at work and trying to keep things as normal as possible at home for the couple's two children, who he said are coping well: "Jamie is 17 and approaching adulthood and understands why she is doing it and is okay, but obviously his mum is away and he has his sixth year exam results coming and he misses her.

"Olivia seems to be fine too. She understands her mum has MS, which stops her doing things with her and she knows this treatment is to help her to be a better mother.

"I've been trying as much as possible to keep her occupied with play dates and sleepovers."

The couple have been impressed by the level of care in the clinic and Lindsay has had the chance to meet and get to know other MS patients from all over the world.

Liam has nothing but admiration for her strength and the positive way she is enduring the extreme procedures she faces.

He adds: "Lindsay is the most determined person you could ever possibly meet. She has had bad days and it can be demoralising for her but she is determined to be as positive as she can be.

"It is not a cure. MS doesn't have a cure but we hope it will stop the progress of the disease. We just hope it will halt it by rebooting her immune system and hopefully stop the severe relapses."

Liam adds: "It is desperately hard and stressful for all of us and we have to put a positive spin, in the grand scheme of things it is just for a month of her life."

Follow Lindsay's journey at Facebook/Lindsay's Last Hope - HSCT in Russia

Fundraising continues as the family has only until the end of the month to reach their target. You can support this young mum in her bid to enjoy a normal quality of life by going to https://www.gofundme.com/lindsay-slasthope

Belfast Telegraph

View original post here:
Northern Ireland mum fighting MS: Russian medics are now my last hope - Belfast Telegraph

Mike Whaley mwhaley@fosters.com @mwhaley25

Greg Friel can deal with the pain, as bad as it can be. Its the uncertainty about his future well-being that makes life difficult.

A former basketball star at Oyster River High School and Dartmouth College, Greg, 38, was diagnosed with relapsing remitting multiple sclerosis in 2010.

This unpredictable, often disabling disease of the central nervous system has weakened his body, particularly his legs below the knees, to the point where he often has to get around with a cane, and sometimes a walker.

Im in constant pain, he said. Its terrible. But Ive got a beautiful wife. Ive got a business where Im my own boss. Its a challenge. If you know the Friels, were up for a challenge. But its scary.

Fortunately, for Greg, there might be a light at the end of the tunnel. Next month, he will fly to Russia with his Uncle Bob for hematopoietic stem cell transplantation (HSCT). After being on the waiting list for three-plus years, Greg was recently granted admission to the treatment program.

The catch is that the cost for travel and treatment will be around $100,000. The treatment is not covered by insurance, so Gregs wife, Anastagia, has set up a GoFundMe page to raise funds to pay for the trip and treatment (https://www.gofundme.com/gregfrielhsct). As of Saturday morning, nearly $53,000 has been raised in three weeks.

Greg flies to Moscow on Sept. 24 for the month-long treatment, which begins on Sept. 26 at Piragov Hospital.

MS is so unpredictable, Anastagia said. Its hard to see my husband, a pillar of strength in the family, going through a weak time.

Hes such a positive person, she added. Hes charismatic. Theres such a light around him. Its hard to deny his charisma, and hes charming.

The treatment includes chemotherapy, where Greg said they shock your system down to zero. Good stem cells are injected, so basically its a stem cell rebirth.

It wasnt easy for Greg to reach out for help. An independent financial advisor in Boston, he was used to being the one helping out. It was in his nature to give.

My wife, my mom and my siblings told me I needed to open myself up, said Greg, who stands 6-foot-5. It was difficult. But if you get it early, you get proactive and you get things done, you can be in fine shape.

Thats the high-road approach Greg is taking.

Thats the athletic mentality, he said. Youre competitive because you care.

nnn

Greg comes from primo competitive stock. His dad, the late Gerry Friel, was the head mens basketball coach at the University of New Hampshire for 20 seasons (1969-89).

Greg is the middle child of five siblings. All of them played basketball at Oyster River and all five scored over 1,000 career points (Keith tallied over 2,000 points). They also all played Division I college basketball: Jennifer (UNH), Keith (Notre Dame, Virginia), Greg (Dartmouth), Jeremy (UNH) and Jilliane (UNH).

Greg and Keith starred at Oyster River in the mid-1990s, leading the Bobcats to back-to-back Class I championships in 1995 and 96.

Keith speaks fondly of those years playing with his brother. Greg was always two steps ahead and always competing. He did the little things, all the extra stuff that others didnt want to do. He loved to win, even if that meant diving for a ball or taking charges.

Greg was Wojo before Wojo, Keith said, referencing the feisty former Duke University guard of the late 1990s, Steve Wojciechowski. He was always firing up the other team, getting in their heads.

Plus he had that deadly 3-point stroke.

Greg graduated in 1997, attended New Hampton School for a post-graduate year where he counted future NBA star Darius Songaila (whos still a close friend) and Pistol Pete Maravichs son, Jason, among his teammates. Greg started for New Hampton and led them to the New England Class A prep championship game where they lost to Maine Central Institute.

Originally committed to the University of North Carolina at Wilmington, Greg decided to accept an offer from Dartmouth, coached by Somersworth native Dave Faucher, a former assistant at UNH under Gregs dad.

Two of Fauchers sons played at Lebanon High School, whom Oyster River beat in the 1995 Class I championship, 55-52. Greg set a tournament championship record with five 3-pointers in that game, a record he still shares 22 years later with two other players.

UNC-Wilmington would not let him out of his commitment, so he had to sit out a year before joining the Dartmouth team in the fall of 1999.

Greg played four years for the Big Green, serving as a captain as a senior. He graduated with a degree in economics and a minor in sociology.

As a player he got the chance to compete against both his brothers, although Jeremy laughs, I was on the bench while he was playing. I didnt get in.

Greg has been a financial advisor for 14 years, the last nine as his own man, running his own business.

He met his future wife while judging a beauty pageant in Las Vegas in 2009. A successful model, Anastagia has been Miss Teen Florida USA, Miss Florida USA and Miss Bahama Universe. She has also appeared in Sports Illustrateds swimsuit issue.

She actually didnt want to be at that particular pageant in 2009, but went at her moms behest and finished second.

They communicated on Facebook and it blossomed from there. Greg and Anastagia were married in May of 2014.

nnn

In 2010, when Greg was diagnosed with MS, it started with headaches.

I was feeling weak, he said. I was working 80-90 hours a week, so I was thinking it could have been that. I just kept getting weaker and weaker, my legs mostly. I was feeling lethargic. I didnt have any energy.

His legs hurt. He described it as a charley horse: You cant move, he said. Youre stuck in mud. It felt like youre cutting (to the basket) and someone knees your leg muscle. Thats what it felt like all the time.

At its worse, Greg said he couldnt move, couldnt walk, couldnt get out of bed.

Greg took a very aggressive drug called Tysabri for 4 years that cost $22,000 a month for an infusion and was partially covered by insurance. But it wasnt a cure and he didnt know the long-term effects. That was a concern since he and Anastagia want to have children.

Now theres hope with the Russian treatment.

Gregs cousin, Brendan Friel, who suffered from the same MS, went to Russia for treatment and is back in good health.

He just had his three-year stem cell anniversary, Greg said. And now hes working full-time.

Anastagia said they did their research. (The treatment) is invasive, but its got a good track record, she said.

What Greg finds irritating is that the procedure is covered by insurance for cancer, ALS and rheumatoid arthritis, but not MS.

Its crazy, he said.

As expected, its been difficult for his family.

Its heart-wrenching, said Joan, his mom. Its been more debilitating in the past year than ever. Hes going downhill since Thanksgiving of last year. Its one little setback after another this time. He has to do something; otherwise it will get so much worse.

Joan said shes there as a mom. Thats my job and I embrace it for all my children. Im a sounding board.

She added, I dont need to be intrusive. Im there if they need me and want me and, sometimes, if they dont.

Greg maintains an upbeat attitude.

Im good, he said. I try to stay positive. Ive always been a pretty positive person mentally.

nnn

The Friels have been touched by the outpouring of donations in such a short time, some from old adversaries or teammates Greg hasnt seen in 20 years.

Its not like one person wrote a check for $20,000, Greg said. Over 300 people have donated. Its very humbling. Its nice to see the support.

Later this month there will be a fundraiser at The Warehouse Bar & Grille, 40 Broad Street, in Boston to raise funds for Gregs treatment. It is being put together by a couple of old basketball opponents, Cliff Dever (Timberlane) and Marshall Chrane (Bishop Brady).

Chrane was on the Brady team that Gregs OR team beat in the 1996 Class I final, 58-49. Chrane returned the favor in 1997, hitting two foul shots with no time on the clock to beat Oyster River by a point in the tournament quarterfinals, Gregs last high school game.

The fundraiser will take place from 1 to 4 p.m. on Aug. 27.

There will be raffles, which include, among others, items donated by former pro and college football coach, Chip Kelly; UNH hockey coach Dick Umile and UMass-Amherst athletic director Ryan Bamford, Gregs old AAU teammate.

The journey to get Greg his treatment is certainly gaining momentum.

Were determined to get this right, he said.

Anastagia agrees.

I dont want anyone to be fighting alone, she said. Were committed to fighting this thing together.

Which is what good teammates do.

More:
Former basketball star Greg Friel in fight of his life - Sports - fosters ... - Foster's Daily Democrat

A new research document with title Europe Mesenchymal Stem Cells Market by Manufacturers, Countries, Type and Application, Forecast to 2022 covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like Germany, UK, France, Russia, Italy and important players/vendors such as Thermo Fisher, Bio-Techne, ATCC, etc The report will help user gain market insights, future trends and growth prospects for forecast period of 2017-2022

Request a sample report @ https://www.htfmarketreport.com/sample-report/643003-europe-mesenchymal-stem-cells-marketMesenchymal Stem Cells (MSC), also termed Mesenchymal Stromal Cells, are multipotent cells that can differentiate into a variety of cell types and have the capacity for self-renewal.

Scope of the Report:

This report focuses on the Mesenchymal Stem Cells in Europe market, especially in Germany, UK, France, Russia, and Italy. This report categorizes the market based on manufacturers, countries, type and application.

Market Segment by Manufacturers, this report covers

Lonza

Thermo Fisher

Bio-Techne

ATCC

MilliporeSigma

PromoCell GmbH

Genlantis

Celprogen

Cell Applications

Cyagen Biosciences

Axol Bioscience

Market Segment by Countries, covering

Germany

UK

France

Russia

Italy

Market Segment by Type, covers

Human MSC

Mouse MSC

Rat MSC

Other

Market Segment by Applications, can be divided into

Research Institute

Hospital

Others

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/643003-europe-mesenchymal-stem-cells-market

There are 17 Chapters to deeply display the Europe Mesenchymal Stem Cells market.

Chapter 1, to describe Mesenchymal Stem Cells Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;

Chapter 2, to analyze the manufacturers of Mesenchymal Stem Cells, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers in Europe, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the Europe market by countries, covering Germany, UK, France, Italy and Russia, with sales, price, revenue and market share of Mesenchymal Stem Cells, for each country, from 2012 to 2017;

Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type and application, from 2012 to 2017;

Chapter 7, 8, 9, 10 and 11, to analyze the key countries by manufacturers, Type and Application, covering Germany, UK, France, Italy and Russia, with sales, revenue and market share by manufacturers, types and applications;

Chapter 12, Mesenchymal Stem Cells market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2017 to 2022;

Chapter 13, to analyze the manufacturing cost, key raw materials and manufacturing process etc.

Chapter 14, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);

Chapter 15, to describe Mesenchymal Stem Cells sales channel, distributors, traders, dealers etc.

Chapter 16 and 17, to describe Mesenchymal Stem Cells Research Findings and Conclusion, Appendix, methodology and data source

.Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/643003-europe-mesenchymal-stem-cells-market

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=643003Contact Us:CRAIG FRANCIS (PR & Marketing Manager)sales@htfmarketreport.comPh: +1 (206) 317 1218

Go here to see the original:
Europe Mesenchymal Stem Cells Market Forecast 2022 Study covering Strategies, Application, Growth Estimation and ... - satPRnews (press release)

Imagine only being able to see the things in front of you in soft focus, and just in black and white. For people with the genetic eye condition achromatopsia those are just some of the side effects. But, researchers are testing a new treatment designed to cure the condition by fixing the gene responsible.

Each time Tara Cataldo prepares to leave her house, she has to make sure her face is completely shielded from the sun.

I need to have very dark, very tinted sunglasses to feel comfortable outside and to see really well. Cataldo said.

Cataldo has achromatopsia, a genetic condition that makes her eyes incredibly sensitive to light. She is also very nearsighted; even while wearing glasses or contacts, she can only see clearly at a very short distance.

I cannot drive a car so I rely on public transportation and my bike to get around. Cataldo explained.

"There are currently no approved and no effective treatments for achromatopsia, said University of Florida surgical ophthalmologist Christine Kay.

Kay is working to change that. She is one of a handful of experts testing a gene therapy.

For achromatopsia the cells we have to target are cone cells responsible for decreased vision and color vision and those are cells at the very bottom layer of the retina, Kay explained.

Using a tiny cannula, surgeons deliver a normal copy of one of two mutated genes; the CNGA3 or CNGB3 gene, directly into the eye - restoring vision.

Cataldos myopia is so severe that her risk of retinal detachment from any retinal surgery is high, which rules her out for the current trial. In the meantime, Cataldo says shes learned to adapt to achromatopsia and live without limitations.

And I hope all young achromats learn the same thing, Cataldo said.

Kay says if the gene could eventually be delivered to the surface of the retina; additional patients, like Cataldo, could be treated. Applied Genetic Technologies Corporation, the biotech company that developed the therapies, and several U.S. universities have successfully tested this therapy in dogs and sheep.

Published at 2:10 PM CDT on Aug 16, 2017

Read the original here:
Achromatopsia: Gene Therapy Cures Eye Disease? - NBC 5 Dallas-Fort Worth

DUBLIN, August 16, 2017 /PRNewswire/ --

The "Global Cancer Gene Therapy Market 2017-2021" report has been added to Research and Markets' offering.

The global cancer gene therapy market to grow at a CAGR of 20.63% during the period 2017-2021.

The report, Global Cancer Gene Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is favorable government regulations for gene therapy programs. Gene therapy has been a big hope for the individuals suffering from rare diseases and various forms of cancers. Cancer is one of the biggest life-threatening diseases across the globe and has been a huge point of concern for the healthcare providers. This has led to rising support to R&D activities in cancer gene therapy from various governments.

According to the report, one driver in the market is rising geriatric population. The global geriatric population is continues to grow at a faster pace due to several factors such as rapidly falling fertility rates and growing life expectancy due to better medical facilities. The US Census Bureau reported that the total population aging 65 years and above was estimated at 617 million in 2015 and is expected to rise to 1,566 million by 2050. Asia has the largest and fastest growing aging population due to several factors such as the huge population of the region, government policies such as one child policy of China has reduced the addition of young population, and higher investment in the healthcare sector has led to better medical facilities and longer life expectancy.

Further, the report states that one challenge in the market is high cost of gene therapy treatment. The sky-high cost of gene therapy has made it a point of debate across the globe. One of the major causes for the exorbitant cost of gene therapy is the requirement of intensive clinical trials. The gene therapy needs to be tailored to suit the genetic acceptance for each individual, unlike small and large molecule drug clinical trials where the trials are done in large and random samples. In the clinical trials of gene therapy, the stem cell is extracted from each patient's bone marrow, then the correct version of the gene is mingled with the cell, and the corrected stem cells are introduced to the individual patient.

Key vendors

Other prominent vendors

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Segmentation By Therapy

Part 07: Geographical Segmentation

Part 08: Decision Framework

Part 09: Drivers And Challenges

Part 10: Market Trends

Part 11: Vendor Landscape

Part 12: Key Vendor Analysis

Part 13: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/drvk7v/global_cancer

Media Contact:

Research and Markets Laura Wood, Senior Manager rel="nofollow">press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Link:
Global Cancer Gene Therapy Market to Grow at a CAGR of 20.6% by 2021: Favorable Government Regulations for ... - Markets Insider

LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global cancer gene therapy market is expected to grow at a CAGR of almost 21% during the forecast period.

This research report titled Global Cancer Gene Therapy Market 2017-2021 provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

The rising prevalence rate of cancer has been a huge challenge for the global economies as the disease leads to high rate of mortality and economic losses. The current treatment options available come with many drawbacks such as severe side effects and relapse of cancer. These factors have led to high investment in the R&D for development of various novel therapies with cancer gene therapy being one of the major ones of them. The therapy mainly uses three types of treatment options namely oncolytic virotherapy, gene transfer therapy, and gene-induced immunotherapy.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavios healthcare and life sciences research analysts categorize the global cancer gene therapy market into the following segments by therapy. They are:

Looking for more information on this market? Request a free sample report

Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Oncolytic virotherapy

Oncolytic virotherapy is one of the fastest growing treatment modality. In this therapy, the anti-cancer cells specifically destroy the cancer cells without causing harm to the normal cells. Each virus has a specific cellular tropism that determines which tissue will be preferentially infected by the virus and thus will further lead to the disease.

According to Sapna Jha, a lead oncology research analyst from Technavio, The oncolytic virotherapy has shown encouraging results in the pre-clinical studies. The novel treatment option holds great opportunity to make a significant effect on quality and length of the life of the individual. Adenovirus is the most commonly used virus in oncolytic virotherapy.

Gene transfer

Gene transfer or gene insertion is one of the most exciting and emerging cancer treatment methods. The therapy is expected to be the fastest growing type of therapy in the cancer gene therapy market. This is a radical new treatment method that involves the introduction of a new gene into the cancer cell or the surrounding tissues.

Genes with different functions have been proposed for this therapy; some of them include antiangiogenesis genes, cellular stasis genes, and suicide genes. Many different viral vectors are used to deliver these genes, Adenovirus being most common of them. Other than viral vectors, certain non-viral methods are also studied in the various clinical trial, which includes oligodendromer DNA coatings and naked DNA transfer, adds Sapna.

Gene-induced immunotherapy

Immunotherapy works on the concept of boosting the immune system of the individual to target and destroy cancer cells. However, traditional immunotherapy has shown limited success rate in the field. Various gene therapy techniques are being used to overcome this limitation.

The next-generation gene-induced immunotherapy vaccines are already in clinical trial. Gene-induced immunotherapy is a type of gene therapy where genetically engineered genes are used to generate an immune response against cancer. Growing knowledge and understanding of mechanisms regulating the initiation and maintenance of cytotoxic immune response has led to the designing of several genetic immunization strategies.

The top vendors highlighted by Technavios research analysts in this report are:

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View post:
Cancer Gene Therapy Market - Forecasts and Opportunity Assessment by Technavio - Business Wire (press release)

The global research antibodies market (including reagents) is projected to reach USD 12.60 Billion by 2022 from USD 9.33 Billion in 2017, growing at a CAGR of 6.2% during the forecast period.

Factors such as the increasing R&D activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and growing collaboration between industries and academic institutes are the key drivers of the market.

The report analyzes the global research antibodies market (including reagents) by product, technology, application, end user, and region. Based on product, the market is segmented into reagents and antibodies. The reagents segment accounted for the major share of the research antibodies market (including reagents) in 2016. This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.

Furthermore, based on type, the reagents market has been further segmented into media & sera, stains & dyes, fixatives, buffers, probes, solvents, enzymes, and others (controls, stabilizers, and diluents). The media & sera segment is expected to dominate the market in 2016 due to its high usage in all types of assays, culture procedures, and techniques.

Market Dynamics

Key Market Drivers

Key Market Opportunities

Key Challenges

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Research Antibodies Market, By Product

7 Research Antibodies Market, By Technology

8 Research Antibodies Market, By Application

9 Research Antibodies Market, By End User

10 Research Antibodies Market, By Region

11 Competitive Landscape

12 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/xgmch2/research

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-research-antibodies-market-2017-2022---increasing-demand-for-personalized-medicine-and-protein-therapeutics-300505197.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Read this article:
Global Research Antibodies Market 2017-2022 - Increasing Demand for Personalized Medicine and Protein ... - PR Newswire (press release)

Vibrent Health's cloud-based precision medicine platform has gained authority to operate from the National Institutes of Health, a certification that it meets federal privacy and security standards and paving the way for the company's work on the landmark research cohort that will fuel the Precision Medicine Initiative

"This ATO certification marks a significant milestone for Vibrent in its journey to power the next generation of personalized medicine," said the company's CEO Praduman Jain, in a statement.

Vibrent's SaaS platform combines genomic information with data from electronic health records, medical devices, wearables and more.

[Also:NIH All of Us program gearing up for 'precision engagement,' Eric Dishman says]

It will be the technology around which the All of Us Research Program will be based as the precision medicine project works to enroll more than one million participants in its cohort to understand how genomics, lifestyle, behavioral, and environmental factors impact an individuals health.

In addition to NIH, Vibrent's technology is at use at Johns Hopkins, Stanford, the U.S. Veterans Administration, UnitedHealth Group and Medtronic.

For the ATO certification, the company worked with Coalfire, a third-party assessment organization, to develop security plans, policies, procedures, scanning, SSP, and pen testing, per FISMA risk management framework, to ensure the integrity of its platform, officials said. Coalfire confirmed that Vibrent Health has the necessary operational and technical controls in place to provide a secure environment for federal systems, bureaus, departments, and their supporting entities.

Twitter:@MikeMiliardHITNEmail the writer: mike.miliard@himssmedia.com

Like Healthcare IT News on Facebook and LinkedIn

Read more from the original source:
NIH gives nod to Vibrent Health for precision medicine work - Healthcare IT News

Technology could speed the process of precision medicine; Beaverton firm is at forefront.

Ganapati "Gans" Srinivasa is not a doctor, but he just might hold the key to saving millions of lives.

Srinivasa is famous for being the chief architect of the Xeon processor, a 400 MHz Pentium microprocessor from Intel for use in mid-range enterprise servers and workstations. The device is found in most modern technological devices.

Srinivasa is chief executive officer of Omics Data Automation, a resident company at the Oregon Technology Business Center and one of five winners of the 2017 Beaverton Challenge winners. The company is designing and selling software in the precision medicine area to aggregate data for cancer treatment centers and hospitals.

"We can talk about gadgets, but so what? This is the Holy Grail," Srinivasa said of his current project to assist medical professionals working with cancer patients who are faced with a mountain of data from a wide and confusing array of sources.

And he's not alone in that opinion.

"A patient with a newly diagnosed cancer may undergo many different types of tests, but the results of these tests exist in separate data silos," said Dr. Chris Corless, director of the Knight Diagnostic Laboratories, Oregon Health & Science University. A data silo is a separate database or set ofdatafiles that are not part of an organization's enterprise-widedataadministration.

"Omics will aggregate and analyze the very large quantity of data contained across all of these silos, which will result in faster diagnostics and more effective treatments," Corless said.

According to Srinivasa, there are currently about 16 million cancer survivors in the United States and, of those, about 600,000 are expected to die from some form of cancer, making it the second deadliest disease next to heart disease.

Precision medicine is a lot more than stethoscopes and X-ray machines."It's an eye-opener how dependent precision medicine is on computation,"? saidMichael Wrimm, Ph.D, a principal with Omics.

The treatment of cancer isn't justa "race with time," it's also an expensive effort, Srinivasa said. His goal is to provide this service in a price range of $100 to $500 per patient to compute and store information for 10 years.

Omics recently was awarded a grant from the National Science Foundation for $224,903 to develop technology that will help patients receive faster and more accurate diagnosis and treatment. This capability has the potential to help patients with cancer and other serious medical conditions. Omics also recently received a $500,000 contract with the University of California, Los Angeles Hospital.

The vision of Omics Data Automation in the Oregon Technology Business Center Incubator, is for effective precision medicine treatment each patient has be characterized, analyzed and targeted with a plan tailored to inhibit their cancer. Precision treatment is an informatics enterprise that aims to expedite and perfect the process so the most precise, tailored treatment plan can be generated in one day using all the information available.

Srinivasa said the specialized computation of treatment for cancer and what Omics is doing is a timesaver and a lifesaver. Omics has grown from about four principals at the beginning of the year to 11 contributors to the project now.

Wrimm said precision medicine seems exotic, but the company tries to make it accessible to all.

Omics develops infrastructure for aggregating multidimensional data to enable customers to build and scale up clinical practices while keeping the costs low, so lifesaving technology is available for everyone.

Omics is designing and selling software in the precision medicine area to aggregate data for cancer treatment centers and hospitals.

Wrimm and Srinivasa said they both left their "cushy Intel jobs" to make a difference in the world.

Omics looks for groups of population cohorts that have a similar set of variations.

Steve Morris, executive director of the Oregon Technology Business Center, said, "I think this project really has exciting potential this whole idea of personalized medicine takes you (the patient) into account right down to the genome. It's a great example of incubation. Gans (Srinivasa) is awesome in terms of technology and this has excellent potential to make a very big splash worldwide."

The broader impact/commercial potential of this small business innovation project is that patient medical information comes in many diverse forms including genomic sequences, medical images and clinical observations.

The integration of the various data sources across patient populations have shown to reveal patterns and similarities among patients, which inform treatment options. With advances in imaging and genomic sequencing technologies, the sheer volume of available information is growing exponentially, straining current computational approaches and creating an imminent need for scalable data integration, Srinivasa said.

The ability to overcome the data mountain opens the door to support precision medicine and provide enhanced services to medical institutions. With Omics innovations, patients can receive faster and more accurate diagnoses and treatments, clinicians can deliver verified treatment decisions through patient cohort comparison, hospitals have better standard of care and society overall will potentially be empowered by supporting global treatment options and well-informed pharmaceutical development, Srinivasa added.

The project develops a scalable aggregation, a technique for improving the interactive behavior of database systems, and analysis of factors and circumstances that cause a patient's symptoms to improve or worsen. The project blends all that information to help create personalized diagnosis and therapy for each patient.

But bringing all that information together in one place for the doctors to find is the trick.

The project aggregates features from genomics (the branch of molecular biology concerned with the structure, function, evolution and mapping of genomes), imaging and clinical characterization of patients. This enables identification of groups of patients based on both genotypes (the genetic constitution of an individual organism) and phenotypes (the set of observable characteristics of an individual resulting from the interaction of its genotype with the environment).

For more information, visit omicsautomation.com.

Continued here:
Computing cancer - Pamplin Media Group

Dr. Dwayne E. Carter,Post Doctoral Researcher, Tissue Applications.

(PRESS RELEASE) A national of Grenada, Dr. Dwayne E. Carter received his formation in the sciences at the Grenada Boys Secondary School and the T. A. Marryshow Community College in his hometown of Saint Georges.

Dwayne would later migrate to the United States to further pursue his passion for medicine and his curiosity to better understand and cure diseases that plague the human race. After years of study, Dwayne completed his doctoral training in cell biology at the University of Texas Medical Branch where he primarily focused on acute alcohol induced liver injury.

In 2016, he joined ORGANOVO Holdings Inc. as a post-doctoral researcher in liver tissue bioengineering with a focus on modeling progressive liver diseases. Throughout his graduate training, Dwayne received numerous awards for meritorious research from national scientific meetings and has two publications in peer reviewed journals.

When asked about the advice that he would give to young persons in the sub region that may be interested in an investigative science career, Dwayne said: This is a long road but the journey is worth it. A tip is to always make goals for yourself and plan strategic ways to achieve those goals.

Also be prepared to fight for what you want! Very few things are handed to you in this world, so brace yourself for times of adversity because you will inevitably be faced with challenges and the way you deal with them determines your success or failure.

At this stage in my life I consider myself a fighter, I look forward to the challenges because Ive learnt that they bring forward my best, he said.

Dr. Carter will be delivering a presentation on Modeling Human Biology, Drug Response and Progressive Liver Disease Using 3D Bioprinted Human Liver Tissue at the Committee Lecture Hall at TSRI, La Jolla, California at 7:00pm today, August 16, 2017.

ABOUT THE PRESENTATION:

Nonalcoholic fatty liver disease (NAFLD) is a chronic condition that originates as lipid accumulation within hepatocytes (steatosis) and progresses into nonalcoholic steatohepatitis (NASH), characterised by lipid accumulation, inflammation, oxidative stress, and fibrosis. NAFLD is now recognised as the most common cause of chronic liver disease, with a prevalence of 25% worldwide, and is projected to become the leading indication for liver transplant by 2025.

Despite decades of research in rodents and 2D cell cultures, the mechanisms of NAFLD progression, therapeutic approaches and non-invasive diagnostics are still resoundingly absent. Thus, there is a significant need for a more predictive human multicellular 3D in vitro model to study the progression of steatosis into NASH.

Using immune competent ExVive Human Liver Tissue, an in vitro 3D bioprinted liver, Dr. Carter will show preliminary data where the key features of NASH such as steatosis, fibrosis and inflammation will be modeled via nutrient overload followed by inflammatory stimulation using prototypical inducers.

ABOUT THE OECS FEATURE SERIES:

The OECS Feature Series is an initiative that seeks to feature the accomplishments of consummate professionals from OECS Member States making strides within the region and in the Diaspora.

The project highlights one outstanding OECS national per month and aims to inspire the regions youth to think big and open their minds to extraordinary possibilities through the success stories of their OECS peers.

Criteria for nominations include: being a national of an OECS Member State; possessing an academic distinction of the highest order; scientific invention; high political accomplishment (regionally and in the Diaspora); and extraordinary community or national service achieved (regionally and in the Diaspora).

This article was posted in its entirety as received by stlucianewsonline.com.This media house does not correct any spelling or grammatical error within press releases and commentaries.The views expressed therein are not necessarily those of stlucianewsonline.com, its sponsors or advertisers.

See the rest here:
OECS highlights outstanding Grenadian making strides in biotechnology - St. Lucia News Online

Finnish Mets Group has started its mill for bio-based products. The 1.2bn investments production capacity is 1.3 million tonnes of softwood pulp a year.

According to the Finnish company, pulp deliveries from the new mill to customers will begin in early September 2017. Mets said that its old pulp mill in nekoski has been shut down and is currently be dismantled.

The new mill will achieve its nominal capacity approximately a year after start-up. Mets Group will be the worlds biggest producer of softwood pulp, said Ilkka Hml, CEO of Mets Fibre. The mill will produce 1.3 million tonnes of pulp per year, along with other bio-based products such as tall oil and turpentine. New bioproducts include product gas from bark, sulphuric acid from the mills odorous gases, and biogas and biofuel pellets from sludge.

The mill will be a platform for production of new bio-based products among them lignin products, textile fibres, and biocomposites. The next-generation bioproduct mill will not use any fossil fuels at all, since it will generate all of the energy that it needs from side streams. In terms of its energy efficiency, the mill is among the world's best within its industry. Its degree of self-sufficiency in electricity is 240 per cent.

Follow this link:
Mets Group started up its bioproduct mill - European Biotechnology

Needle moving action has been spotted in Prana Biotechnology Ltd (PBT.AX) as shares are moving today onvolatility0.00% or $0.00 from the open.TheASX listed companysaw a recent bid of $0.055 and155324shares have traded hands in the session.

Some investment professionals believe that a great way to find, study, and invest in equities without getting completely overwhelmed, is to have a systematic and research driven approach. Of course, the same approach may not work for everybody. One investor may find one way that works for them, and another investor might find something completely different when it comes to portfolio picking. Trading and investing can carry a major emotional component. Even after careful research, being able to pull the trigger on a trade may still involve squashing the fear that comes with the thought of being wrong. Finding continued success in the stock market may entail keeping the portfolio balanced, but also finding the courage to get in when necessary, or get out when needed. Developing this confidence may take a lot of practice and determination.

Now letstake a look at how the fundamentals are stacking up for Prana Biotechnology Ltd (PBT.AX). Fundamental analysis takes into consideration market, industry and stock conditions to help determine if the shares are correctly valued. Prana Biotechnology Ltd currently has a yearly EPS of -0.02. This number is derived from the total net income divided by shares outstanding. In other words, EPS reveals how profitable a company is on a share owner basis.

Another key indicator that can help investors determine if a stock might be a quality investment is the Return on Equity or ROE. Prana Biotechnology Ltd (PBT.AX) currently has Return on Equity of -26.73. ROE is a ratio that measures profits generated from the investments received from shareholders.

In other words, the ratio reveals how effective the firm is at turning shareholder investment into company profits. A company with high ROE typically reflects well on management and how well a company is run at a high level. A firm with a lower ROE might encourage potential investors to dig further to see why profits arent being generated from shareholder money.

Another ratio we can look at is the Return on Invested Capital or more commonly referred to as ROIC. Prana Biotechnology Ltd (PBT.AX) has a current ROIC of -26.73. ROIC is calculated by dividing Net Income Dividends by Total Capital Invested.

Similar to ROE, ROIC measures how effectively company management is using invested capital to generate company income. A high ROIC number typically reflects positively on company management while a low number typically reflects the opposite.

Turning to Return on Assets or ROA, Prana Biotechnology Ltd (PBT.AX) has a current ROA of -24.71. This is a profitability ratio that measures net income generated from total company assets during a given period. This ratio reveals how quick a company can turn its assets into profits. In other words, the ratio provides insight into the profitability of a firms assets. The ratio is calculated by dividing total net income by the average total assets.

A higher ROA compared to peers in the same industry, would suggest that company management is able to effectively generate profits from their assets. Similar to the other ratios, a lower number might raise red flags about managements ability when compared to other companies in a similar sector.

Read more:
Prana Biotechnology Ltd (PBT.AX) A Look Inside the Technicals - Morgan Research

Scientists at the University of Oxford in the UK devised a way to produce tissues in self-contained cells that support the structures to keep their shape. Photo: iStock

London: Oxford scientists have developed a new method to 3D-print laboratory-grown cells to form living structures, an advance that may help repair damaged body parts. The approach could revolutionise regenerative medicine, enabling the production of complex tissues and cartilage that would potentially support, repair or augment diseased and damaged areas of the body, researchers said.

Scientists at the University of Oxford in the UK devised a way to produce tissues in self-contained cells that support the structures to keep their shape. The cells were contained within protective nanolitre droplets wrapped in a lipid coating that could be assembled, layer-by-layer, into living structures. Producing printed tissues in this way improves the survival rate of the individual cells, and allowed the team to improve on current techniques by building each tissue one drop at a time to a more favourable resolution.

To be useful, artificial tissues need to be able to mimic the behaviours and functions of the human body, researchers said. The method enables the fabrication of patterned cellular constructs, which, once fully grown, mimic or potentially enhance natural tissues.

We were aiming to fabricate three-dimensional living tissues that could display the basic behaviours and physiology found in natural organisms, said Alexander Graham, scientist at OxSyBio (Oxford Synthetic Biology).

To date, there are limited examples of printed tissues, which have the complex cellular architecture of native tissues. Hence, we focused on designing a high-resolution cell printing platform, from relatively inexpensive components, that could be used to reproducibly produce artificial tissues with appropriate complexity from a range of cells including stem cells, said Graham. The research was published in the journal Scientific Reports.

Excerpt from:
New method to 3D print living tissues developed - Livemint

Wednesday, August 16, 2017 5:33 p.m. EDT

(Reuters) - Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

The 40-week trial tested two dosages of Novo's once-weekly drug, semaglutide, in addition to initial standard-of-care therapy metformin, against Eli Lilly and Co's dulaglutide plus metformin.

Novo Nordisk said its drug was statistically significant in reducing glucose levels and lowering body weight in about 1,200 patients suffering from type 2 diabetes, when compared with dulaglutide.

Type 2 diabetes, closely linked to obesity, accounts for more than 90 percent of all diabetes cases.

The trial results could have been offset by an increase in cases of diabetic retinopathy, which leads to vision loss, Guggenheim analyst Tony Butler noted.

However, Novo Nordisk said on Wednesday the number of patients reporting an adverse event of diabetic retinopathy was low and comparable in both the arms.

"We are excited about the potential of semaglutide to set a new standard for treatment of type 2 diabetes," the company said.

Semaglutide and dulaglutide belong to the GLP-1 category of drugs which imitate an intestinal hormone that stimulates the production and absorption of insulin.

With both the drugs offering significant benefits, pricing will continue to be the most important factor in the diabetes space, Jefferies analyst Heffrey Holford said in a client note.

Lilly's dulaglutide, which is sold under the brand name Trulicity, is one of the main growth drivers of the drugmaker's success.

Dulaglutide generated sales of $480 million in the second quarter, accounting for about half of the company's new product sales.

"While we project that Lilly will retain its leadership position in the once-weekly segment, Novo has made headway with its oral formulation that could potentially shift the market dynamics in its favor over the longer term," Barclays analysts said.

(Reporting by Divya Grover in Bengaluru; Editing by Shounak Dasgupta)

See more here:
Novo Nordisk's diabetes drug succeeds in key trial - WHTC

A 12-year-old girl with Type 1 Diabetes says she was not permitted to ride the water slides at a public water park in Kettering because of the insulin pump attached to her body.

Mom Beth McBride claims the city of Kettering broke the law by violating the Americans With Disabilities Act, while city and waterpark officials are not yet commenting on the issue.

"She was in tears and upset, as she has every right to be, I mean she was discriminated against basically," McBride told Fox 45.

She snapped a picture of daughter Alexis looking defeated right after she was denied a ride on one of the waterslides at the "adventure reef waterpark."

12-year-old Alexis said a lifeguard told her the reason she could not ride was the insulin pump attached to her right hip.

"It was that one slide and that one lifeguard, that when I walked up there she pointed at my insulin pump and said you cannot go on the slide with that on," Alexis said.

Alexis said the pump makes her insecure and this was the first occasion that she had worn a two-piece bathing suit and exposed it in public.

"It's completely true bliss, the insulin is actually in a chamber here," McBride said showing Fox 45 the small external pump, "it's made to be worn in water parks, it's made to be worn in the ocean, in showers and bathtubs, she's allowed to wear it."

McBride related it to having Alexis' pancreas functioning outside her body. She said if it is removed, Alexis could die.

McBride also said the lifeguard did not explain the reason behind asking Alexis to remove the pump.

"I said do you realize that's an ADA violation, she has a medical handicap, the insulin pump cannot be removed," McBride said.

According to title three of the Americans With Disabilities Act, "providers of public accommodations must provide you with services that are not any different from those they provide people without a disability. They must not screen out or exclude you because of your disability."

McBride took her concern about the violation to park managers who she says took an incident report Monday night.

"She should be able to wear a medical devices with pride," McBride said.

"I'm not as different as everybody else is and I shouldn't be singled out from everybody else that's having fun," said Alexis.

McBride said she wanted to raise awareness for Type 1 Diabetes related issues and wants to make sure this does not happen to anyone else at any catering facilities.

This article originally appeared on Fox 45 Now

Go here to read the rest:
Girl with diabetes banned from water slide because of insulin pump, mom claims - Fox News

Health District offering a free Diabetes Self-Management Workshop

KENNEWICK, Wash. Benton-Franklin Health District health professionals said diabetes effects a significant number of people in Benton and Franklin counties.

Now the health district is offering a free workshop to help reduce this health threat.

"One in every two people has pre-diabetes, one in every two people," Registered Dietitian and Nutritionist Laili Abd Latif stressed.

Latif said a staggering number of people in Benton and Franklin counties are suffering from diabetes or are at high risk, but dont know.

"Because it's almost like a silent disease, you dont really know the disease until you get tested," she said.

Many of the at-risk groups include the Hispanic, Asian, and African-American populations.

If you have pre-diabetes, she said with intervention like changing your diet, adding physical activity, and developing a healthier lifestyle, pre-diabetes can be reversed.

Abd Latif and other health advocates are urging people who are over the age of 40, overweight, have a baby larger than nine pounds, or have a history of diabetes to get screened.

"If you know, you can work towards improving yourself, she said. But if you don't know, you'll be walking around for 10 years with diabetes, and then the complication of diabetes already sets in."

She said by not managing your diabetes, it will drive up medical costs and increase medical complications later in life.

"When you have diabetes, you don't just have diabetes, you also have high blood pressure, you have high tri-glyceride, and high cholesterol," Abd Latif said.

Thats why the Benton-Franklin Health District is offering a free Diabetes Self-Management Workshop.

The Diabetes Self-Management class will be offered on Thursdays from 4:00 to 6:30 p.m., from August 17 to September 21. The workshop will be held at Benton-Franklin Health District, 7102 W Okanogan Place in Kennewick.

The evidence-based program from Stanford School of Medicine empowers people with diabetes to maintain and improve their health.

It is led by people who have diabetes themselves, so they understand what the diabetes community is going through.

"So its really more of a support group," said Liza Gonzalez, community health worker and program coordinator for the workshop.

Gonzalez said the six-week class will teach you ways to deal with fatigue and pain, improve nutrition and exercise choices, communicate better with healthcare providers and family members and develop weekly action plans.

"If we can learn to be healthy and if we can take action in how to be healthy, this is a starting point for you," she said.

Unfortunately, Gonzalez said many times people don't take advantage of these free health education programs.

"We're all busy, she admitted. But where are we going to be if we don't take care of ourselves first?"

Gonzalez and Abd Latif believe that together they can transform the lives of those in living with diabetes in our community.

The educational class is open to all people with diabetes, those with family members with diabetes, or those who care for diabetes. To register for the class or for more information about the free workshops, call Lisa Gonzalez at 509-460-4216.

The Benton Franklin Health District and the Tri-Cities Diabetes Coalition is also hosting a Diabetes Awareness Fair Oct. 7 from 10:00 a.m. 1:00 p.m. at Pasco High School. Admission is free and there will be door prizes.

Read the original post:
Health District is offering a free Diabetes Self-Management Workshop - KEPR 19

Dr. Meranda Nakhla is the lead author of a study, which was published in BMJ Open Diabetes Research & Care, that calls for action to help adolescents with diabetes transition to adult care. Credit: McGill University Health Centre

Adolescence can be a turbulent period of life, with struggles to establish autonomy, identity issues and risk-taking behaviours. For young adults with a chronic illness such as type 1 diabetes, this transition phase also brings about other challenges as they assume an increased responsibility for their overall health. A new study from the Research Institute of the McGill University Health Centre (RI-MUHC) sheds light on gaps in transition care practice in Quebec, pointing out a lack of standardized policies across pediatric diabetes centres. These findings, which were published in the open-access journal BMJ Open Diabetes Research & Care, highlight a need for the evaluation and development of targeted interventions at multiple levels to improve the transition process.

"The transition from pediatric to adult care is a huge and complex process that is not unique to type 1 diabetes. It also occurs with other childhood chronic diseases such as cystic fibrosis or in kidney transplant recipients,'' says the study's senior author Dr. Meranda Nakhla, a pediatric endocrinologist at the Montreal Children's Hospital of the MUHC and an assistant professor of Pediatrics at McGill University. "Previous studies have shown that transition is a vulnerable period when adolescents tend to fall out of medical care, meaning that once they leave pediatric care to be transferred to adult care they do not have regular follow up for their chronic illness.''

According to Dr. Jan Hux, chief science officer at Diabetes Canada, which funded the study, adolescence is a time when young people may start to rebel against the daily rigours of living with this 24/7 disease and take risks that may affect their health in later years. "As noted in Diabetes Canada's Clinical Practice Guidelines, there needs to be a well-prepared and supported move to adult care that includes a transition coordinator, patient reminders, and education," she says. "Having strong transitional care and support as they move to this new stage of life can have a great impact on their lives. As this study points out, more work needs to be done to ensure these needs are being effectively met."

Currently, one in four Canadians lives with diabetes and Quebec has one of the highest incidence rates of the disease among children in the world (32 per 100,000 per year). Type 1 diabetesan illness in which the body produces little or no insulin and requires daily insulin injections for lifeis one of the most common chronic diseases in childhood.

In this study, researchers focused on the perspective of pediatric care providers from academic, non-academic and rural health facilities in Quebec. They conducted in-depth interviews with diabetes nurses, educators, pediatricians and pediatric endocrinologists from 12 centres across the province between June and November 2015. The care providers were asked for their perspective, experiences and the barriers that they see are in the way of achieving a successful transition from pediatric to adult care.

"We found there were huge gaps in transition care practices such as the lack of a standardized transition care policy, limited communication between the pediatric and adult healthcare settings and an absence of structure for pediatric care providers to implement transition care practices,'' explains Dr. Nakhla, who is also a scientist from the Centre for Outcomes Research and Evaluation at the RI-MUHC. "Good intentions are there and everyone recognizes that this transition is important but more structure and guidance are needed for pediatric providers to implement it better within their practices.''

The study reported that pediatric care providers recognized the importance of transition care but only 25 per cent reported having any formal and structured transition preparation and planning in their diabetes centres. Some of the barriers that pediatric providers perceived as important were the lack of adult care providers and a multidisciplinary team in the adult care setting, less flexibility in scheduling adult healthcare appointments, patients' struggles with multiple new responsibilities such as starting secondary education, employment or moving away from home. Another barrier that was addressed was the pediatric providers' lack of time in planning for transition and lack of resources, including human resources, in implementing transition care services.

"As healthcare practitioners, we need to start the transition process early and not in the year before adolescents get transferred to adult care. We also need to make more efforts to engage families and guide parents to progressively give their teenagers more responsibility without taking unnecessary risks," says Dr. Nakhla

Researchers are currently using a health administrative database in Quebec to look at what happens to these young adults in terms of hospitalization, emergency department visits and health outcomes when they transfer to adult care.

Explore further: Better info needed in transfer from peds to adult care for T1DM

More information: Meranda Nakhla et al, Improving the transition from pediatric to adult diabetes care: the pediatric care provider's perspective in Quebec, Canada, BMJ Open Diabetes Research & Care (2017). DOI: 10.1136/bmjdrc-2017-000390

See original here:
Study calls for action to help adolescents with diabetes transition to adult care - Medical Xpress

BANGKOK, Aug. 17, 2017 /PRNewswire/ -- Mr. NoppadonPakprot, Deputy Governorfor Tourism Products and Business,Tourism Authority of Thailand (TAT) presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest "Functional & Regenerative Medicine" innovation in Thailand.

Mr. NoppadonPakprot, Deputy Governorfor Tourism Products and Business at TAT said, "Thailand has long been recognized as a world destination for medical tourism. According to a report by VISA and Oxford Economics, Thailand has once more been confirmed as one of Asia's top medical tourism destinations. Thailand now has 58 JCI-accredited hospitals, more than any other Southeast Asian country."

The Amazing Thailand Health and Wellness Tourism Showcase 2017, under the concept "Thailand: a Paradise for Longevity", showcased Thailand as a destination for longevity products and services.

Thailand has adopted the latest innovative medicine of the century: "Functional & Regenerative Medicine," the most popular health trend in the world. In fact, Thailand is the first and only country in Asia that has specialized Functional & Regenerative Medicine hospitals, namely Better Being Hospital and MALI hospital

Moreover, Thailand has become an anti-aging center in Asia with the largest number of American Academy of Anti-Aging Medicine-certified medical professionals in Asia with 500 doctors.

"Recently, the government implemented new medical tourism policies extending the visitor stay period to 90 days for members of CLMV countries andTaiwan in order to accommodate medical tourists traveling to Thailand. In addition, the long-stay visa has also been extended to 10 years for 14 countries as follow: Japan, Australia, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Sweden, Switzerland, UK, Canada and the U.S. These two recent policies should further enhance the positioning of Thailand to be a world-class medical tourism hub recognized the world over."

Mr. Noppadonnoted: "This is the 4th such event that TAT has organized, and this year we proudly present the top 44 Health and Wellness providers in Thailand. This event will display the potential of Thailand along with its plethora of health and wellness products to international awareness. It will also provide a marketing platform for Thai health and wellness providers to discuss prospective business deals with medical tourism facilitators and travel agencies from across the globe."

The one-day event highlighted why Thailand is a "Paradise for Longevity", along with holding an informative presentation on the concept of "Functional & Regenerative Medicine. In the afternoon, buyers had the chance to discuss business deals with the top 44 health and wellness providers in Thailand, including: General Hospital, Plastic Surgery Hospital, Regenerative Functional Medicine Hospital, Anti-Aging Clinic, Cosmetic & Aesthetic Clinic, Dental Clinic, Cell Therapy Clinic, and Lab Check Up, all of whom were ready to discuss prospective business deals with international buyers.

Mr. NoppadonPakprot concluded as follows: "We hope that this event will further strengthen the awareness of Thailand as the premier destination for health and wellness tourism, and that the trade event would help generate more than 500 million Baht to the Thai economy."

Ms. Jittima Udayachalerm, Director, Royal Orchid Plus Business Unit said, "Royal Orchid Plus is delighted to be part of this global medical tourism event at this time. We've created exciting marketing activities to support this project. "We've organized a special event, inviting Royal Orchid Plus Platinum and Gold members to come and get health check-ups for free, and also given them the chance to meet and buy special packages from the hospitals and clinics at the event. Additionally, we will promote an exclusive health and wellness deal to Royal Orchid Plus members through our online channels, including email, social media, and our website."

SOURCE Amazing Thailand Health and Wellness Tourism Showcase 2017

View original post here:
TAT holds global medical tourism event: "Amazing Thailand Health and Wellness Tourism Showcase 2017," focusing ... - Markets Insider

NEW YORK, Aug. 16, 2017 /PRNewswire/ -- Factors driving the growth of this market include the increasing number of genomics research activities for studying diseases; advances in biobanking and the growing trend of conserving cord blood stem cells of newborns; government & private funding to support regenerative medicine research, and the growing need for cost-effective drug discovery and development. On the other hand, the growth of this market is hindered to some extent due to the high cost of automation and issues related to biospecimen sample procurement.

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

"Automated storage is expected to register the highest CAGR during the forecast period" The biobanking market is classified by storage type into manual and automated storage. The automated storage type segment is expected to grow at a higher rate during the forecast period. This is attributed to launch of new and advanced automated storage equipment and increasing demand for the quality storage of samples.

"Regenerative medicine to dominate the market during the forecast period"The biobanking market is segmented based on applications regenerative medicine, life science research, and clinical research. In 2017, the regenerative medicine segment is expected to command the largest share and is also estimated to grow at the fastest rate as compared to other segments. This can be attributed to increasing research activities in the field of regenerative medicine and rising demand for well-annotated and quality biosamples for research.

"Asia-Pacific is estimated to grow at the highest CAGR during the forecast period" Geographically, the biobanking market is dominated by North America, followed by Europe. The Asia-Pacific region is estimated to grow at the fastest rate which can be attributed to the large population in China and India, increasing research in regenerative medicine, and improving life sciences research infrastructure in the region.

The primary interviews conducted for this report can be categorized as follows:

The key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.).

Study Coverage:The report analyses the biobanking market by product and service, sample type, storage type, application and regions. Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market.

Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the type, products, applications, end users, and regions.

Key benefits of buying the Report:This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

Contact Clare: rel="nofollow">clare@reportlinker.comUS:(339) 368 6001 Intl:+1 339 368 6001

View original content:http://www.prnewswire.com/news-releases/biobanking-market-by-product-and-serviceequipment-consumables-services-software-sample-type-blood-products-human-tissues-cell-lines-nucleic-acids-application-regenerative-medicine-life-science-clinical-research---g-300505662.html

SOURCE Reportlinker

See the rest here:
Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood ... - Markets Insider

The most aggressive variant of brain tumour glioblastoma has an average survival rate of 15 months. There is therefore an urgent need for new treatment strategies for this group of patients. A research team from Lund University in Sweden has now identified new factors which may affect the tumour cells' ability to resist treatment. The study has been published in Cell Reports.

The most common form of brain tumour is called glioma. Patients with the most aggressive variant glioblastoma are treated intensively with surgery, radiation and chemotherapy. Despite this, the tumour inevitably returns as a treatment-resistant lesion.

"There are strong indications that only a small proportion of the cells in the tumour those known as cancer stem cells are resistant to treatment and therefore affect the recurrence of the tumour. In our studies, partly on mice and partly on human glioma cells, we mapped the signal pathways that apparently differ from treatment-resistant to treatment-sensitive glioma cells. Part of the explanation for this resides in the cells' response to oxygen deprivation," explains Alexander Pietras, who headed the study at Lund University.

Oxygen deprivation often occurs in tumour cells, partly because they grow faster than new blood vessels can be formed, and partly because the blood vessels in the tumour are often of inferior quality and therefore unable to supply oxygen to the same extent. Researchers already knew that oxygen-deprived tumours are often more aggressive. Now, the research team in Lund has discovered that a specific marker (CD44) present on the surface of the cancer stem cells interacts with a protein (HIF-2a) which is central to the adaptation to oxygen deprivation.

"When a cell becomes deprived of oxygen, HIF is stabilised, leading to a number of adaptations which save energy and contribute to the formation of new blood vessels, among other things. In cancer stem cells, this signal pathway seems to be active even when the cells are not being deprived of oxygen. Our findings indicate that the interaction with CD44 which is specific to cancer stem cells is crucial to this oxygen-independent stabilisation of HIF."

In normal cases, these signal pathways are tightly regulated, but in the cancer stem cells in cases of glioblastoma, these functions appear to be partly disabled. The findings explain how cancer stem cells can exploit HIF despite often being located in the parts of the brain tumour with the best oxygen supply, right next to blood vessels. The cancer stem cells' response to oxygen deprivation is thus regulated differently, resulting in more aggressive cancer cells, which do not respond to treatment. These cancer stem cells could be those responsible for recurrence of the disease, according to the researchers behind the study.

"We want to use this new knowledge to affect the resistant cells in a more treatment-sensitive direction, by impairing the signal pathway between CD44 and HIF-2a a potentially useful strategy in a number of other tumour forms as well, in which HIF and CD44 are thought to be significant, such as kidney cancer," concludes Alexander Pietras.

Explore further: Brain cancer study reveals therapy clues

More information: Elinn Johansson et al. CD44 Interacts with HIF-2 to Modulate the Hypoxic Phenotype of Perinecrotic and Perivascular Glioma Cells, Cell Reports (2017). DOI: 10.1016/j.celrep.2017.07.049

Journal reference: Cell Reports

Provided by: Lund University

The rest is here:
Researchers map brain tumour cells' adaptation to oxygen deprivation - Medical Xpress